Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-23T23:43:47.024Z Has data issue: false hasContentIssue false
  • English
  • Français

The potential role of FNDC5/irisin in various liver diseases: awakening the sleeping beauties

Published online by Cambridge University Press:  13 June 2022

Xiaoyu Wang ,
Lihong Mao ,
Chaoqun Li ,
Yangyang Hui ,
Zihan Yu ,
Mingyu Sun ,
Yifan Li ,
Gaoyue Guo ,
Wanting Yang  and
Binxin Cui
...Show all authors
Xiaoyu Wang
Affiliation:
Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China Tianjin Institute of Digestive Disease, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China
Lihong Mao
Affiliation:
Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China Tianjin Institute of Digestive Disease, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China
Chaoqun Li
Affiliation:
Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China Department of Internal Medicine, Tianjin Hexi Hospital, Qiongzhou Road 43, Hexi District, Tianjin 300202, China
Yangyang Hui
Affiliation:
Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China Tianjin Institute of Digestive Disease, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China
Zihan Yu
Affiliation:
Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China Tianjin Institute of Digestive Disease, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China
Mingyu Sun
Affiliation:
Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China Tianjin Institute of Digestive Disease, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China
Yifan Li
Affiliation:
Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China Tianjin Institute of Digestive Disease, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China
Gaoyue Guo
Affiliation:
Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China Tianjin Institute of Digestive Disease, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China
Wanting Yang
Affiliation:
Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China Tianjin Institute of Digestive Disease, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China
Binxin Cui
Affiliation:
Department of Gastroenterology, Tianjin Medical University General Hospital Airport Hospital, East Street 6, Tianjin Airport Economic Area, Tianjin 300308, China
Xiaofei Fan
Affiliation:
Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China Tianjin Institute of Digestive Disease, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China
Chao Sun*
Affiliation:
Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China Tianjin Institute of Digestive Disease, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China Department of Gastroenterology, Tianjin Medical University General Hospital Airport Hospital, East Street 6, Tianjin Airport Economic Area, Tianjin 300308, China
*
Author for correspondence: Chao Sun, E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Fibronectin type III domain-containing protein 5 (FNDC5) is a transmembrane protein and the precursor of irisin, which serves as a systemic exerkine/myokine with multiple origins. Since its discovery in 2012, this hormone-like polypeptide has rapidly evolved to a component significantly involved in a gamut of metabolic dysregulations and various liver diseases. After a decade of extensive investigation on FNDC5/irisin, we are still surrounded by lots of open questions regarding its diagnostic and therapeutic values. In this review, we first concentrated on the structure–function relationship of FNDC5/irisin. Next, we comprehensively summarised the current knowledge and research findings regarding pathogenic roles/therapeutic applications of FNDC5/irisin in the context of non-alcoholic fatty liver disease, fibrosis, liver injury due to multiple detrimental insults, hepatic malignancy and intrahepatic cholestasis of pregnancy. Moreover, the prominent molecules involved in the underlying mechanisms and signalling pathways were highlighted. As a result, emerging evidence reveals FNDC5/irisin may act as a proxy for diagnosing liver disease pathology, a sensitive biomarker for assessing damage severity, a predisposing factor for surveilling illness progression and a treatment option with protective/preventive impact, all of which are highly dependent on disease grading and contextually pathological features.

Keywords

AMPKbiomarkerFNDC5irisinliver diseasenon-alcoholic fatty liver diseasePGC1α
Type
Review
Information
Expert Reviews in Molecular Medicine , Volume 24 , 2022 , e23
Copyright
Copyright © The Author(s), 2022. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

*

These authors have contributed equally to this work and share first authorship.

References

Aydin, S et al. (2014) A comprehensive immunohistochemical examination of the distribution of the fat-burning protein irisin in biological tissues. Peptides 61, 130–136.10.1016/j.peptides.2014.09.014CrossRefGoogle ScholarPubMed
Bostrom, P et al. (2012) A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481, 463–468.10.1038/nature10777CrossRefGoogle ScholarPubMed
Perakakis, N et al. (2017) Physiology and role of irisin in glucose homeostasis. Nature Reviews. Endocrinology 13, 324–337.10.1038/nrendo.2016.221CrossRefGoogle ScholarPubMed
Huh, JY et al. (2014) Irisin stimulates muscle growth-related genes and regulates adipocyte differentiation and metabolism in humans. International Journal of Obesity 38, 1538–1544.10.1038/ijo.2014.42CrossRefGoogle ScholarPubMed
Ma, EB et al. (2019) Irisin exerts inhibitory effect on adipogenesis through regulation of Wnt signaling. Frontiers in Physiology 10, 1085.10.3389/fphys.2019.01085CrossRefGoogle ScholarPubMed
Xiong, XQ et al. (2015) FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity. Biochimica et Biophysica Acta 1852, 1867–1875.10.1016/j.bbadis.2015.06.017CrossRefGoogle ScholarPubMed
Cui, B et al. (2022) Therapeutic potential of Saccharomyces boulardii in liver diseases: from passive bystander to protective performer? Pharmacological Research 175, 106022.10.1016/j.phrs.2021.106022CrossRefGoogle ScholarPubMed
Byass, P (2014) The global burden of liver disease: a challenge for methods and for public health. BMC Medicine 12, 159.CrossRefGoogle ScholarPubMed
Trepo, C, Chan, HL and Lok, A (2014) Hepatitis B virus infection. Lancet 384, 2053–2063.10.1016/S0140-6736(14)60220-8CrossRefGoogle ScholarPubMed
Asrani, SK et al. (2021) Reducing the global burden of alcohol-associated liver disease: a blueprint for action. Hepatology 73, 2039–2050.10.1002/hep.31583CrossRefGoogle Scholar
Younossi, ZM et al. (2016) Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84.10.1002/hep.28431CrossRefGoogle ScholarPubMed
Kabarra, K, Golabi, P and Younossi, ZM (2021) Nonalcoholic steatohepatitis: global impact and clinical consequences. Endocrine Connections 10, R240–RR47.10.1530/EC-21-0048CrossRefGoogle ScholarPubMed
Maak, S et al. (2021) Progress and challenges in the biology of FNDC5 and irisin. Endocrine Reviews 42, 436–456.10.1210/endrev/bnab003CrossRefGoogle ScholarPubMed
Askari, H et al. (2018) A glance at the therapeutic potential of irisin against diseases involving inflammation, oxidative stress, and apoptosis: an introductory review. Pharmacological Research 129, 44–55.CrossRefGoogle Scholar
Young, MF, Valaris, S and Wrann, CD (2019) A role for FNDC5/irisin in the beneficial effects of exercise on the brain and in neurodegenerative diseases. Progress in Cardiovascular Diseases 62, 172–178.CrossRefGoogle ScholarPubMed
Schumacher, MA et al. (2013) The structure of irisin reveals a novel intersubunit beta-sheet fibronectin type III (FNIII) dimer: implications for receptor activation. Journal of Biological Chemistry 288, 33738–33744.10.1074/jbc.M113.516641CrossRefGoogle ScholarPubMed
Raschke, S et al. (2013) Evidence against a beneficial effect of irisin in humans. PLoS ONE 8, e73680.10.1371/journal.pone.0073680CrossRefGoogle ScholarPubMed
Rabiee, F et al. (2020) New insights into the cellular activities of Fndc5/irisin and its signaling pathways. Cell & Bioscience 10, 51.10.1186/s13578-020-00413-3CrossRefGoogle ScholarPubMed
Kim, H et al. (2018) Irisin mediates effects on bone and Fat via alphaV integrin receptors. Cell 175, 1756–1768 e17.CrossRefGoogle Scholar
Estell, EG et al. (2020) Irisin directly stimulates osteoclastogenesis and bone resorption in vitro and in vivo. Elife 9, e58172.10.7554/eLife.58172CrossRefGoogle ScholarPubMed
Bi, J et al. (2020) Irisin reverses intestinal epithelial barrier dysfunction during intestinal injury via binding to the integrin alphaVbeta5 receptor. Journal of Cellular and Molecular Medicine 24, 996–1009.10.1111/jcmm.14811CrossRefGoogle Scholar
Bi, J et al. (2020) Exercise hormone irisin mitigates endothelial barrier dysfunction and microvascular leakage-related diseases. JCI Insight 5, e136277.10.1172/jci.insight.136277CrossRefGoogle ScholarPubMed
Oguri, Y et al. (2020) CD81 controls beige fat progenitor cell growth and energy balance via FAK signaling. Cell 182, 563–577. e20.10.1016/j.cell.2020.06.021CrossRefGoogle ScholarPubMed
Zhang, N et al. (2020) A novel biphenyl compound IMB-S7 ameliorates hepatic fibrosis in BDL rats by suppressing Sp1-mediated integrin alphav expression. Acta Pharmacologica Sinica 41, 661–669.CrossRefGoogle ScholarPubMed
Sun, F et al. (2019) Interleukin-8 promotes integrin beta3 upregulation and cell invasion through PI3K/Akt pathway in hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research: CR 38, 449.10.1186/s13046-019-1455-xCrossRefGoogle ScholarPubMed
Younossi, Z et al. (2018) Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nature Reviews. Gastroenterology & Hepatology 15, 11–20.CrossRefGoogle ScholarPubMed
Huang, DQ, El-Serag, HB and Loomba, R (2021) Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nature Reviews. Gastroenterology & Hepatology 18, 223–238.10.1038/s41575-020-00381-6CrossRefGoogle ScholarPubMed
Hester, D et al. (2020) Among Medicare patients with hepatocellular carcinoma, non-alcoholic fatty liver disease is the most common etiology and cause of mortality. Journal of Clinical Gastroenterology 54, 459–467.10.1097/MCG.0000000000001172CrossRefGoogle ScholarPubMed
Soleimani, D et al. (2021) Protective effects of propolis on hepatic steatosis and fibrosis among patients with nonalcoholic fatty liver disease (NAFLD) evaluated by real-time two-dimensional shear wave elastography: a randomized clinical trial. Phytotherapy Research 35, 1669–1679.10.1002/ptr.6937CrossRefGoogle ScholarPubMed
Soleimani, D et al. (2021) Effect of propolis supplementation on athletic performance, body composition, inflammation, and oxidative stress following intense exercise: a triple-blind randomized clinical trial. Food Science & Nutrition 9, 3631–3640.CrossRefGoogle ScholarPubMed
Chalasani, N et al. (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328–357.10.1002/hep.29367CrossRefGoogle ScholarPubMed
Park, MJ et al. (2015) New role of irisin in hepatocytes: the protective effect of hepatic steatosis in vitro. Cellular Signalling 27, 1831–1839.10.1016/j.cellsig.2015.04.010CrossRefGoogle ScholarPubMed
Liu, TY et al. (2016) FNDC5 alleviates hepatosteatosis by restoring AMPK/mTOR-mediated autophagy, fatty acid oxidation, and lipogenesis in mice. Diabetes 65, 3262–3275.10.2337/db16-0356CrossRefGoogle ScholarPubMed
Mo, L et al. (2016) Irisin is regulated by CAR in liver and is a mediator of hepatic glucose and lipid metabolism. Molecular Endocrinology 30, 533–542.CrossRefGoogle ScholarPubMed
So, WY and Leung, PS (2016) Irisin ameliorates hepatic glucose/lipid metabolism and enhances cell survival in insulin-resistant human HepG2 cells through adenosine monophosphate-activated protein kinase signaling. International Journal of Biochemistry & Cell Biology 78, 237–247.CrossRefGoogle ScholarPubMed
Tang, H et al. (2016) Irisin inhibits hepatic cholesterol synthesis via AMPK-SREBP2 signaling. EBioMedicine 6, 139–148.10.1016/j.ebiom.2016.02.041CrossRefGoogle ScholarPubMed
Motta, VF et al. (2017) Treating fructose-induced metabolic changes in mice with high-intensity interval training: insights in the liver, white adipose tissue, and skeletal muscle. Journal of Applied Physiology (1985) 123, 699–709.10.1152/japplphysiol.00154.2017CrossRefGoogle ScholarPubMed
Petta, S et al. (2017) Fibronectin type III domain-containing protein 5 rs3480 A > G polymorphism, irisin, and liver fibrosis in patients with nonalcoholic fatty liver disease. Journal of Clinical Endocrinology and Metabolism 102, 2660–2669.10.1210/jc.2017-00056CrossRefGoogle Scholar
Canivet, CM et al. (2020) Hepatic FNDC5 is a potential local protective factor against non-alcoholic fatty liver. Biochimica et Biophysica Acta, Molecular Basis of Disease 1866, 165705.10.1016/j.bbadis.2020.165705CrossRefGoogle ScholarPubMed
Li, DJ et al. (2021) NAD(+)-boosting therapy alleviates nonalcoholic fatty liver disease via stimulating a novel exerkine Fndc5/irisin. Theranostics 11, 4381–4402.CrossRefGoogle ScholarPubMed
Zhu, W et al. (2021) Exercise-Induced irisin decreases inflammation and improves NAFLD by competitive binding with MD2. Cells 10, 3306.10.3390/cells10123306CrossRefGoogle ScholarPubMed
Medhat, D et al. (2021) Influence of irisin on diet-induced metabolic syndrome in experimental rat model. Journal of Complementary & Integrative Medicine 18, 347–354.10.1515/jcim-2020-0030CrossRefGoogle ScholarPubMed
Kwon, J et al. (2021) DSS-induced colitis is associated with adipose tissue dysfunction and disrupted hepatic lipid metabolism leading to hepatosteatosis and dyslipidemia in mice. Scientific Reports 11, 5283.10.1038/s41598-021-84761-1CrossRefGoogle ScholarPubMed
Alamdari, AF et al. (2021) Melatonin as a promising modulator of aging related neurodegenerative disorders: role of microRNAs. Pharmacological Research 173, 105839.10.1016/j.phrs.2021.105839CrossRefGoogle ScholarPubMed
Gjorgjieva, M et al. (2019) miRNAs and NAFLD: from pathophysiology to therapy. Gut 68, 2065–2079.10.1136/gutjnl-2018-318146CrossRefGoogle ScholarPubMed
Yu, Y et al. (2022) MicroRNA-665-3p exacerbates nonalcoholic fatty liver disease in mice. Bioengineered 13, 2927–2942.CrossRefGoogle ScholarPubMed
Chen, J et al. (2022) Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis of longitudinal cohort studies. Saudi Journal of Gastroenterology 28, 92–100.Google ScholarPubMed
Seo, DY et al. (2014) Effects of aged garlic extract and endurance exercise on skeletal muscle FNDC-5 and circulating irisin in high-fat-diet rat models. Nutrition Research and Practice 8, 177–182.10.4162/nrp.2014.8.2.177CrossRefGoogle ScholarPubMed
Liu, TY et al. (2015) Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes. Clinical Science 129, 839–850.CrossRefGoogle ScholarPubMed
Niranjan, SB et al. (2019) Recombinant irisin induces weight loss in high fat DIO mice through increase in energy consumption and thermogenesis. Biochemical and Biophysical Research Communications 519, 422–429.10.1016/j.bbrc.2019.08.112CrossRefGoogle ScholarPubMed
Canfora, EE et al. (2019) Gut microbial metabolites in obesity, NAFLD and T2DM. Nature Reviews. Endocrinology 15, 261–273.10.1038/s41574-019-0156-zCrossRefGoogle ScholarPubMed
Kwon, J et al. (2020) Comprehensive amelioration of high-fat diet-induced metabolic dysfunctions through activation of the PGC-1alpha pathway by probiotics treatment in mice. PLoS ONE 15, e0228932.10.1371/journal.pone.0228932CrossRefGoogle ScholarPubMed
Chang, HC and Guarente, L (2014) SIRT1 and other sirtuins in metabolism. Trends in Endocrinology and Metabolism 25, 138–145.10.1016/j.tem.2013.12.001CrossRefGoogle ScholarPubMed
Kheiripour, N et al. (2019) Hepatoprotective effects of silymarin on liver injury via irisin upregulation and oxidative stress reduction in rats with type 2 diabetes. Iranian Journal of Medical Sciences 44, 108–117.Google ScholarPubMed
Shen, HH et al. (2019) Genistein ameliorated obesity accompanied with adipose tissue browning and attenuation of hepatic lipogenesis in ovariectomized rats with high-fat diet. Journal of Nutritional Biochemistry 67, 111–122.CrossRefGoogle ScholarPubMed
Eser, N et al. (2021) Ameliorative effects of garlic oil on FNDC5 and irisin sensitivity in liver of streptozotocin-induced diabetic rats. Journal of Pharmacy and Pharmacology 73, 824–834.CrossRefGoogle ScholarPubMed
Zhang, HJ et al. (2013) Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. Journal of Hepatology 59, 557–562.10.1016/j.jhep.2013.04.030CrossRefGoogle ScholarPubMed
Polyzos, SA et al. (2014) Irisin in patients with nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental 63, 207–217.10.1016/j.metabol.2013.09.013CrossRefGoogle ScholarPubMed
Shanaki, M et al. (2017) Lower circulating irisin is associated with nonalcoholic fatty liver disease and type 2 diabetes. Diabetes & Metabolic Syndrome 11(suppl. 1), S467–SS72.CrossRefGoogle ScholarPubMed
Waluga, M et al. (2019) Omentin, vaspin and irisin in chronic liver diseases. Journal of Physiology and Pharmacology 70, 277–285.Google ScholarPubMed
Choi, ES et al. (2014) Association between serum irisin levels and non-alcoholic fatty liver disease in health screen examinees. PLoS ONE 9, e110680.CrossRefGoogle ScholarPubMed
Rizk, FH, Elshweikh, SA and Abd El-Naby, AY (2016) Irisin levels in relation to metabolic and liver functions in Egyptian patients with metabolic syndrome. Canadian Journal of Physiology and Pharmacology 94, 359–362.10.1139/cjpp-2015-0371CrossRefGoogle ScholarPubMed
Moreno-Perez, O et al. (2018) High irisin levels in nondiabetic HIV-infected males are associated with insulin resistance, nonalcoholic fatty liver disease, and subclinical atherosclerosis. Clinical Endocrinology 89, 414–423.CrossRefGoogle ScholarPubMed
Bhanji, RA et al. (2017) Sarcopenia in hiding: the risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis. Hepatology 66, 2055–2065.10.1002/hep.29420CrossRefGoogle ScholarPubMed
Armandi, A et al. (2022) Crosstalk between irisin levels, liver fibrogenesis and liver damage in non-obese, non-diabetic individuals with non-alcoholic fatty liver disease. Journal of Clinical Medicine 11, 635.CrossRefGoogle ScholarPubMed
Martinez-Montoro, JI et al. (2021) Impact of genetic polymorphism on response to therapy in non-alcoholic fatty liver disease. Nutrients 13, 4077.CrossRefGoogle ScholarPubMed
Metwally, M et al. (2019) A polymorphism in the irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR. Journal of Hepatology 70, 494–500.CrossRefGoogle Scholar
Daneshi-Maskooni, M et al. (2019) Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial. BMC Complementary and Alternative Medicine 19, 59.10.1186/s12906-019-2465-0CrossRefGoogle ScholarPubMed
Rahmanabadi, A et al. (2019) Oral alpha-lipoic acid supplementation in patients with non-alcoholic fatty liver disease: effects on adipokines and liver histology features. Food & Function 10, 4941–4952.CrossRefGoogle ScholarPubMed
Trautwein, C et al. (2015) Hepatic fibrosis: concept to treatment. Journal of Hepatology 62(suppl. 1), S15–S24.10.1016/j.jhep.2015.02.039CrossRefGoogle ScholarPubMed
Ellis, EL and Mann, DA (2012) Clinical evidence for the regression of liver fibrosis. Journal of Hepatology 56, 1171–1180.10.1016/j.jhep.2011.09.024CrossRefGoogle ScholarPubMed
Elpek, GO (2014) Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: an update. World Journal of Gastroenterology 20, 7260–7276.CrossRefGoogle ScholarPubMed
Zhou, B et al. (2018) Fibronectin type III domain-containing 5 attenuates liver fibrosis via inhibition of hepatic stellate cell activation. Cellular Physiology and Biochemistry 48, 227–236.10.1159/000491722CrossRefGoogle ScholarPubMed
Dong, HN et al. (2020) Irisin regulates the functions of hepatic stellate cells. Endocrinology and Metabolism 35, 647–655.10.3803/EnM.2020.658CrossRefGoogle ScholarPubMed
Liao, X et al. (2021) Irisin ameliorates endoplasmic reticulum stress and liver fibrosis through inhibiting PERK-mediated destabilization of HNRNPA1 in hepatic stellate cells. Biological Chemistry 402, 703–715.10.1515/hsz-2020-0251CrossRefGoogle ScholarPubMed
Pazgan-Simon, M et al. (2020) Serum concentrations of selected adipokines in virus-related liver cirrhosis and hepatocellular carcinoma. Clinical and Experimental Hepatology 6, 235–242.10.5114/ceh.2020.99517CrossRefGoogle ScholarPubMed
Kukla, M et al. (2020) Irisin in liver cirrhosis. Journal of Clinical Medicine 9, 3158.CrossRefGoogle ScholarPubMed
Zhao, M et al. (2020) Association between serum irisin concentrations and sarcopenia in patients with liver cirrhosis: a cross-sectional study. Scientific Reports 10, 16093.10.1038/s41598-020-73176-zCrossRefGoogle ScholarPubMed
Hou, L et al. (2021) A sex-stratified prognostic nomogram incorporating body compositions for long-term mortality in cirrhosis. JPEN. Journal of Parenteral and Enteral Nutrition 45, 403–413.CrossRefGoogle ScholarPubMed
Wang, Y et al. (2019) Genipin ameliorates carbon tetrachloride-induced liver injury in mice via the concomitant inhibition of inflammation and induction of autophagy. Oxidative Medicine and Cellular Longevity 2019, 3729051.10.1155/2019/3729051CrossRefGoogle Scholar
Barbagelata, A et al. (2007) Time to reperfusion in acute myocardial infarction. It is time to reduce it!. Journal of Electrocardiology 40, 257–264.10.1016/j.jelectrocard.2007.01.007CrossRefGoogle ScholarPubMed
Thirupurasundari, CJ, Jayalakshmi, R and Niranjali Devaraj, S (2005) Liver architecture maintenance by tincture of Crataegus against isoproterenol-induced myocardially infarcted rats. Journal of Medicinal Food 8, 400–404.CrossRefGoogle ScholarPubMed
Kuloglu, T et al. (2014) Irisin: a potentially candidate marker for myocardial infarction. Peptides 55, 85–91.CrossRefGoogle ScholarPubMed
Aydin, S et al. (2017) The effect of iloprost and sildenafil, alone and in combination, on myocardial ischaemia and nitric oxide and irisin levels. Cardiovascular Journal of Africa 28, 389–396.10.5830/CVJA-2017-025CrossRefGoogle ScholarPubMed
Aydin, S et al. (2015) Effect of carnosine supplementation on apoptosis and irisin, total oxidant and antioxidants levels in the serum, liver and lung tissues in rats exposed to formaldehyde inhalation. Peptides 64, 14–23.CrossRefGoogle ScholarPubMed
Erdogan, MA and Yalcin, A (2020) Protective effects of benfotiamine on irisin activity in methotrexate-induced liver injury in rats. Archives of Medical Science: AMS 16, 205–211.10.5114/aoms.2018.80002CrossRefGoogle ScholarPubMed
Unsal, V, Cicek, M and Sabancilar, I (2021) Toxicity of carbon tetrachloride, free radicals and role of antioxidants. Reviews on Environmental Health 36, 279–295.10.1515/reveh-2020-0048CrossRefGoogle ScholarPubMed
Zhao, TM et al. (2020) Bicyclol attenuates acute liver injury by activating autophagy, anti-oxidative and anti-inflammatory capabilities in mice. Frontiers in Pharmacology 11, 463.10.3389/fphar.2020.00463CrossRefGoogle ScholarPubMed
Rabey, E et al. , HA (2021) Green coffee methanolic extract and silymarin protect against CCl4-induced hepatotoxicity in albino male rats. BMC Complementary Medicine and Therapies 21, 19.CrossRefGoogle ScholarPubMed
Pahlavani, N et al. (2020) Molecular and cellular mechanisms of the effects of propolis in inflammation, oxidative stress and glycemic control in chronic diseases. Nutrition and Metabolism 17, 65.10.1186/s12986-020-00485-5CrossRefGoogle ScholarPubMed
Lu, L et al. (2016) Innate immune regulations and liver ischemia-reperfusion injury. Transplantation 100, 2601–2610.10.1097/TP.0000000000001411CrossRefGoogle ScholarPubMed
Bi, J et al. (2019) Irisin alleviates liver ischemia-reperfusion injury by inhibiting excessive mitochondrial fission, promoting mitochondrial biogenesis and decreasing oxidative stress. Redox Biology 20, 296–306.10.1016/j.redox.2018.10.019CrossRefGoogle ScholarPubMed
Youle, RJ and van der Bliek, AM (2012) Mitochondrial fission, fusion, and stress. Science 337, 1062–1065.CrossRefGoogle Scholar
Zhang, J et al. (2020) Involvement of kindlin-2 in irisin's protection against ischaemia reperfusion-induced liver injury in high-fat diet-fed mice. Journal of Cellular and Molecular Medicine 24, 13081–13092.10.1111/jcmm.15910CrossRefGoogle ScholarPubMed
Jing, HR et al. (2018) Fish oil alleviates liver injury induced by intestinal ischemia/reperfusion via AMPK/SIRT-1/autophagy pathway. World Journal of Gastroenterology 24, 833–843.10.3748/wjg.v24.i7.833CrossRefGoogle ScholarPubMed
Saidi, SA et al. (2017) Liver injury following small intestinal ischemia reperfusion in rats is attenuated by Pistacia lentiscus oil: antioxidant and anti-inflammatory effects. Archives of Physiology and Biochemistry 123, 199–205.CrossRefGoogle ScholarPubMed
Fan, X et al. (2019) Irisin contributes to the hepatoprotection of dexmedetomidine during intestinal ischemia/reperfusion. Oxidative Medicine and Cellular Longevity 2019, 7857082.10.1155/2019/7857082CrossRefGoogle Scholar
Bi, J et al. (2020) Irisin improves autophagy of aged hepatocytes via increasing telomerase activity in liver injury. Oxidative Medicine and Cellular Longevity 2020, 6946037.CrossRefGoogle ScholarPubMed
Cheng, Z et al. (2019) Circulating histones are major mediators of multiple organ dysfunction syndrome in acute critical illnesses. Critical Care Medicine 47, e677–ee84.CrossRefGoogle ScholarPubMed
Tan, C et al. (2020) Early systemic inflammatory response syndrome duration predicts infected pancreatic necrosis. Journal of Gastrointestinal Surgery 24, 590–597.CrossRefGoogle ScholarPubMed
Ren, YF et al. (2019) Irisin attenuates intestinal injury, oxidative and endoplasmic reticulum stress in mice with L-arginine-induced acute pancreatitis. World Journal of Gastroenterology 25, 6653–6667.CrossRefGoogle ScholarPubMed
Rhee, C et al. (2017) Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009–2014. JAMA 318, 1241–1249.10.1001/jama.2017.13836CrossRefGoogle Scholar
Kobashi, H, Toshimori, J and Yamamoto, K (2013) Sepsis-associated liver injury: incidence, classification and the clinical significance. Hepatology Research 43, 255–266.CrossRefGoogle ScholarPubMed
Mao, L et al. (2020) The emerging role of ferroptosis in non-cancer liver diseases: hype or increasing hope? Cell Death & Disease 11, 518.10.1038/s41419-020-2732-5CrossRefGoogle ScholarPubMed
Knorr, J, Wree, A and Feldstein, AE (2021) Pyroptosis in steatohepatitis and liver diseases. Journal of Molecular Biology 434, 167271.10.1016/j.jmb.2021.167271CrossRefGoogle ScholarPubMed
Wei, S et al. (2020) Serum irisin levels are decreased in patients with sepsis, and exogenous irisin suppresses ferroptosis in the liver of septic mice. Clinical and Translational Medicine 10, e173.10.1002/ctm2.173CrossRefGoogle ScholarPubMed
Li, Q et al. (2021) Irisin alleviates LPS-induced liver injury and inflammation through inhibition of NLRP3 inflammasome and NF-kappaB signaling. Journal of Receptor and Signal Transduction Research 41, 294–303.CrossRefGoogle ScholarPubMed
Erstad, DJ and Tanabe, KK (2017) Hepatocellular carcinoma: early-stage management challenges. The Journal of Hepatocellular Carcinoma 4, 81–92.10.2147/JHC.S107370CrossRefGoogle ScholarPubMed
Gowhari Shabgah, A et al. (2021) Shedding more light on the role of Midkine in hepatocellular carcinoma: new perspectives on diagnosis and therapy. IUBMB Life 73, 659–669.CrossRefGoogle ScholarPubMed
Yang, S et al. (2021) Role of forkhead box O proteins in hepatocellular carcinoma biology and progression (review). Frontiers in Oncology 11, 667730.CrossRefGoogle Scholar
Wen, Y et al. (2016) Role of osteopontin in liver diseases. International Journal of Biological Sciences 12, 1121–1128.CrossRefGoogle ScholarPubMed
Shi, G et al. (2017) Irisin stimulates cell proliferation and invasion by targeting the PI3K/AKT pathway in human hepatocellular carcinoma. Biochemical and Biophysical Research Communications 493, 585–591.CrossRefGoogle ScholarPubMed
Sun, EJ et al. (2021) Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Biomedicines 9, 1639.CrossRefGoogle ScholarPubMed
Pathria, P, Louis, TL and Varner, JA (2019) Targeting tumor-associated macrophages in cancer. Trends in Immunology 40, 310–327.10.1016/j.it.2019.02.003CrossRefGoogle ScholarPubMed
Arvanitakis, K et al. (2022) Tumor-associated macrophages in hepatocellular carcinoma pathogenesis, prognosis and therapy. Cancers 14, 226.CrossRefGoogle Scholar
Liu, H et al. (2021) FNDC5 induces M2 macrophage polarization and promotes hepatocellular carcinoma cell growth by affecting the PPARgamma/NF-kappaB/NLRP3 pathway. Biochemical and Biophysical Research Communications 582, 77–85.CrossRefGoogle ScholarPubMed
Aydin, S et al. (2016) Irisin immunohistochemistry in gastrointestinal system cancers. Biotechnic and Histochemistry 91, 242–250.10.3109/10520295.2015.1136988CrossRefGoogle ScholarPubMed
Gaggini, M et al. (2017) Increased FNDC5/irisin expression in human hepatocellular carcinoma. Peptides 88, 62–66.CrossRefGoogle ScholarPubMed
Varela-Rodriguez, BM et al. (2016) FNDC5 Expression and circulating irisin levels are modified by diet and hormonal conditions in hypothalamus, adipose tissue and muscle. Scientific Reports 6, 29898.CrossRefGoogle Scholar
Zhang, J et al. (2019) Serum irisin predicts posthepatectomy complications in patients with hepatocellular carcinoma. Disease Markers 2019, 9850191.CrossRefGoogle ScholarPubMed
Pazgan-Simon, M et al. (2020) Serum betatrophin and irisin levels in hepatocellular carcinoma. Journal of Physiology and Pharmacology 71, 113–123.Google ScholarPubMed
Kim, SH et al. (2019) Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors. Journal of Geriatric Oncology 10, 749–756.CrossRefGoogle ScholarPubMed
Williamson, C and Geenes, V (2014) Intrahepatic cholestasis of pregnancy. Obstetrics & Gynecology 124, 120–133.CrossRefGoogle ScholarPubMed
Geenes, V and Williamson, C (2009) Intrahepatic cholestasis of pregnancy. World Journal of Gastroenterology 15, 2049–2066.CrossRefGoogle ScholarPubMed
Menzyk, T et al. (2018) The role of metabolic disorders in the pathogenesis of intrahepatic cholestasis of pregnancy. Clinical and Experimental Hepatology 4, 217–223.CrossRefGoogle ScholarPubMed
Kirbas, A et al. (2016) Maternal circulating levels of irisin in intrahepatic cholestasis of pregnancy. The Journal of Maternal-Fetal & Neonatal Medicine 29, 3483–3487.Google ScholarPubMed
Chen, J, Li, Q and Ma, J (2021) Maternal serum, placental, and umbilical venous blood irisin levels in intrahepatic cholestasis of pregnancy. The Journal of Maternal-Fetal & Neonatal Medicine 34, 2403–2410.CrossRefGoogle ScholarPubMed
Cao, RY et al. (2019) FNDC5: a novel player in metabolism and metabolic syndrome. Biochimie 158, 111–116.CrossRefGoogle ScholarPubMed
Zhao, J et al. (2022) Antioxidant effects of irisin in liver diseases: mechanistic insights. Oxidative Medicine and Cellular Longevity 2022, 3563518.10.1155/2022/3563518CrossRefGoogle ScholarPubMed